首頁 > 市場調查報告書 > 製藥

癌症泌尿科

市場調查報告書

商品編碼

1535598

尿路上皮癌藥物市場 - 按類型（尿路上皮、鱗狀細胞、腺癌）、治療（化療、免疫治療、標靶治療）、性別、給藥途徑（口服、腸胃外）、最終用途、2024 - 2032 年全球預測

Urothelial Cancer Drugs Market - By Types (Urothelial, Squamous Cell, Adenocarcinoma), Treatment (Chemotherapy, Immunotherapy, Targeted Therapy), Gender, Route of Administration (Oral, Parenteral), End-use, Global Forecast 2024 - 2032

出版日期: 2024年06月05日 | 出版商:

Global Market Insights Inc. | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在癌症研究和治療的支持政策和資金的推動下，2024年至2032年全球尿路上皮癌藥物市場的複合年成長率將達到12.1%。各國政府和衛生組織正在投資研究計劃，以開發創新療法並改善尿路上皮癌的治療結果。

例如，2023 年 9 月，政府支持的醫學研究委員會 (MRC) 向解決具有挑戰性的癌症（包括利用人工智慧 (AI) 的研究人員）的創新研究人員提供了 200 萬英鎊的資助。四個英國團隊將各自獲得 50 萬英鎊，用於推進高風險、高回報的項目，旨在治療低存活率的癌症，例如影響大腦、肺部和食道的癌症。這筆資金旨在支持突破性研究，這些研究對於改善這些難以治療的癌症的治療效果至關重要。

對臨床試驗和藥物開發的財政支持加速了新的、有效的藥物推向市場。此外，促進獲得先進治療和支持醫療基礎設施的有利政策可以改善病患照護。這種環境透過推動創新和擴大尿路上皮癌藥物的供應來促進市場成長。

整個尿路上皮癌藥物市場根據類型、治療、性別、給藥途徑、最終用途和地區進行分類。

鱗狀細胞癌細分市場將在 2024 年至 2032 年期間經歷大幅成長。鱗狀細胞癌是一種常見的尿路上皮癌，需要標靶治療來改善患者的預後。精準醫學和免疫療法的進步正在提高治療效果，推動對特殊藥物的需求。旨在發現新療法的研發活動的增加進一步促進了這一領域的擴展。

到 2032 年，門診手術中心 (ASC) 領域將實現強勁成長。 ASC 的便利性和可近性吸引了尋求及時有效護理的患者。此外，ASC 內先進診斷和治療技術的整合確保了高品質的治療，促進了市場擴張。對門診癌症治療的日益偏好推動了該領域對尿路上皮癌藥物的需求。

在癌症病例激增和醫療基礎設施改善的推動下，亞太地區將在整個預測期內取得可觀的進展。中國、日本和印度等國家的尿路上皮癌負擔日益增加，需要加強治療選擇。政府為改善癌症照護所採取的舉措，以及增加對醫療設施和研究的投資，支持了市場成長。大量患者群體的存在和先進醫療技術的採用進一步推動了亞太地區尿路上皮癌藥物市場的發展。

產業生態系統分析
產業影響力
- 成長動力
  - 尿路上皮癌的發生率和盛行率不斷增加
  - 藥物開發過程的進步
  - 增加研發活動
  - 向個人化醫療的轉變有所增加
- 產業陷阱與挑戰
  - 嚴格的法規核准流程
  - 來自替代療法的競爭
成長潛力分析
監管環境
未來市場趨勢
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032 年

主要趨勢
尿路上皮癌
鱗狀細胞癌
腺癌

第 6 章：市場估計與預測：按處理方式，2021 - 2032 年

主要趨勢
化療
免疫療法
標靶治療
聯合藥物治療

第 7 章：市場估計與預測：按性別分類，2021 - 2032 年

主要趨勢
男性
女性

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
注射用

第 9 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
癌症治療中心
門診手術中心
其他最終用戶

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

AstraZeneca Plc
Bristol Myers Squibb
Eisai Co. Ltd.
Exelixis, Inc.
F. Hoffmann La Roche Ltd.
Gilead Science, Inc.
Johnson & Johnson (Janssen Biotech)
Merck & Co. Inc
Merck KGaA
Novartis AG
Pfizer, Inc.
UroGen Pharma, Inc.

簡介目錄

Product Code: 9754

Global Urothelial Cancer Drugs Market will exhibit a 12.1% CAGR from 2024 to 2032, fueled by supportive policies and funding for cancer research and treatment. Governments and health organizations are investing in research initiatives to develop innovative therapies and improve treatment outcomes for urothelial cancer.

For instance, in September 2023, innovative researchers addressing challenging cancers, including those utilizing artificial intelligence (AI), were awarded a £2 million funding boost by the government-supported Medical Research Council (MRC). Four UK-based teams will each receive £500,000 to advance high-risk, high-reward projects aimed at treating cancers with low survival rates, such as those affecting the brain, lungs, and esophagus. This funding aims to support breakthrough research that could be pivotal in improving outcomes for these difficult-to-treat cancers.

Financial support for clinical trials and drug development accelerates the introduction of new, effective drugs to the market. Additionally, favorable policies that promote access to advanced treatments and support healthcare infrastructure enhance patient care. This environment fosters market growth by driving innovation and expanding the availability of urothelial cancer drugs.

The overall Urothelial Cancer Drugs Market is categorized based on types, treatment, gender, route of administration, end use, and region.

The Squamous Cell Carcinoma segment will experience substantial growth over 2024-2032. Squamous cell carcinoma, a common type of urothelial cancer, requires targeted therapies to improve patient outcomes. Advances in precision medicine and immunotherapy are enhancing treatment efficacy, driving demand for specialized drugs. Increased research and development activities aimed at discovering novel therapeutics further contribute to the expansion of this segment.

The Ambulatory Surgical Centers (ASCs) segment will witness robust growth through 2032. ASCs provide a cost-effective and efficient setting for cancer treatments, including minimally invasive surgeries and chemotherapy administration. The convenience and accessibility of ASCs attract patients seeking timely and effective care. Additionally, the integration of advanced diagnostic and therapeutic technologies within ASCs ensures high-quality treatment, fostering market expansion. The growing preference for outpatient cancer treatments propels the demand for urothelial cancer drugs in this segment.

Asia Pacific will lead commendable gains throughout the forecast period, driven by a surge in cancer cases and improvements in healthcare infrastructure. Countries such as China, Japan, and India are experiencing a rising burden of urothelial cancer, necessitating enhanced treatment options. Government initiatives toward improving cancer care, in line with increasing investments in healthcare facilities and research, support market growth. The presence of a large patient population and the adoption of advanced medical technologies further bolster the urothelial cancer drugs market in the Asia Pacific region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence and prevalence of urothelial cancer
  - 3.2.1.2 Advancement in drug development process
  - 3.2.1.3 Increasing research & development activities
  - 3.2.1.4 Increase in shift towards personalized medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory approval process
  - 3.2.2.2 Competition from alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Types, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Urothelial carcinoma
5.3 Squamous cell carcinoma
5.4 Adenocarcinoma

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Chemotherapy
6.3 Immunotherapy
6.4 Targeted therapy
6.5 Combination drug therapies

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Male
7.3 Female

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Oral
8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 Hospitals
9.3 Cancer treatment centers
9.4 Ambulatory surgical centers
9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa